MedTrace Logo

Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients

NCT00990314 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2019-09-16

Study results available
· View outcomes & findings →

Summary

This is an open-label study for patients who participated in the BPS-MR-PAH-203 study and have volunteered to continue treatment for PAH with Beraprost Sodium Modified Release (BPS-MR) tablets.

Conditions

Interventions

DRUG

Beraprost Sodium Modified Release

Sponsors & Collaborators

  • Lung Biotechnology PBC

    lead INDUSTRY

Principal Investigators

  • Aimee Smart · Study Sponsor

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • United States
  • Belgium
  • Czechia
  • Germany
  • Ireland
  • Romania

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00990314 on ClinicalTrials.gov